Literature DB >> 19750031

Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.

Nancy Egerton.   

Abstract

Ixabepilone (Ixempra) is a member of a new class of cytotoxic agents, the epothilones. Epothilones promote tubulin polymerization in vitro and demonstrate antitumor activity. This article reviews the preclinical and clinical data that have led to the approval of ixabepilone for patients with locally advanced or metastatic breast cancer for whom anthracycline and taxane treatments have failed.

Entities:  

Keywords:  anthracyclines; breast cancer; capecitabine; epothilones; ixabepilone; locally advanced; metastatic; taxanes

Year:  2008        PMID： 19750031      PMCID： PMC2730126     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  49 in total

1.  Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules.

Authors:  Claudia J Bode; Mohan L Gupta; Emily A Reiff; Kathy A Suprenant; Gunda I Georg; Richard H Himes
Journal:  Biochemistry       Date:  2002-03-26       Impact factor: 3.162

Review 2.  Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

Authors:  Mariantonietta Colozza; Evandro de Azambuja; Nicola Personeni; Fabienne Lebrun; Martine J Piccart; Fatima Cardoso
Journal:  Oncologist       Date:  2007-03

3.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

4.  Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

Authors:  Maha Hussain; Catherine M Tangen; Primo N Lara; Ulka N Vaishampayan; Daniel P Petrylak; A Dimitrios Colevas; Wael A Sakr; E David Crawford
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

5.  RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

Authors:  Herman Burger; John A Foekens; Maxime P Look; Marion E Meijer-van Gelder; Jan G M Klijn; Erik A C Wiemer; Gerrit Stoter; Kees Nooter
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

Review 6.  Epothilones in breast cancer: review of clinical experience.

Authors:  M N Fornier
Journal:  Ann Oncol       Date:  2007-07       Impact factor: 32.976

Review 7.  Management and preparedness for infusion and hypersensitivity reactions.

Authors:  Heinz-Josef Lenz
Journal:  Oncologist       Date:  2007-05

8.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Authors:  Eva Thomas; Josep Tabernero; Monica Fornier; Pierfranco Conté; Pierre Fumoleau; Ana Lluch; Linda T Vahdat; Craig A Bunnell; Howard A Burris; Patrice Viens; José Baselga; Edgardo Rivera; Valentina Guarneri; Valerie Poulart; Judith Klimovsky; David Lebwohl; Miguel Martin
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

9.  Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

Authors:  Neelima Denduluri; Jennifer A Low; James J Lee; Arlene W Berman; Janice M Walshe; Ujala Vatas; Catherine K Chow; Seth M Steinberg; Sherry X Yang; Sandra M Swain
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

10.  Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

Authors:  Johan Vansteenkiste; Primo N Lara; Thierry Le Chevalier; Jean-Luc Breton; Philip Bonomi; Alan B Sandler; Mark A Socinski; Catherine Delbaldo; Brent McHenry; David Lebwohl; Ronald Peck; Martin J Edelman; Mark Edelman
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544
View more
  5 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.

Authors:  Vinita Takiar; Eric A Strom; Donald P Baumann; Funda Meric-Bernstam; Ricardo H Alvarez; Ana M Gonzalez-Angulo
Journal:  Oncologist       Date:  2013-02-12

3.  CIAPIN1 gene silencing enhances chemosensitivity in a drug-resistant animal model in vivo.

Authors:  X M Wang; S J Gao; X F Guo; W J Sun; Z Q Yan; W X Wang; Y Q Xu; D Lu
Journal:  Braz J Med Biol Res       Date:  2014-03-21       Impact factor: 2.590

4.  Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1.

Authors:  Jing-Hao Wang; Xiu-Wen Wang; Di Qu; Ji-Wen Sun; Fei-Xiao Guo; Dan Lu
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

Review 5.  Perplexing Role of P-Glycoprotein in Tumor Microenvironment.

Authors:  Kianna Robinson; Venkataswarup Tiriveedhi
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.